Sri Lanka Pharmaceutical Manufacturing: Bold $20M Push

Sri Lanka pharmaceutical manufacturing is set to gain a new plant backed by an Indian drugmaker and a local healthcare group. Reports dated 15 October 2026 say Zydus Lifesciences has signed an agreement with the Board of Investment of Sri Lanka (BOI) for a facility in Horana, to be run by the joint venture Zydus Sunshine Lifesciences. Planned investment exceeds $20 million, and commercial operations are expected from 2028.

The project builds on a joint venture first announced on 26 June 2026. Here is what the partners have said, what is still undisclosed, and what the plant could mean for medicine supply in Sri Lanka.

Sri Lanka pharmaceutical manufacturing: key takeaways

• Site: nearly four acres in the BOI zone in Horana, Sri Lanka.
• Investment: more than $20 million, in phases.
• Timeline: commercial operations expected in 2028, subject to project execution and regulatory clearances.
• Focus: medicines for Sri Lanka’s retail market. A report says the first phase covers tablets and capsules.
• Not disclosed: capacity, the full product list and the production schedule by product.

What was announced for Sri Lanka pharmaceutical manufacturing

In the joint-venture announcement of 26 June 2026, Zydus Lifesciences and Sunshine Healthcare said they had formed Zydus Sunshine Lifesciences (Pvt) Ltd to build a pharmaceutical manufacturing facility in Sri Lanka. A foundation stone was laid on the same day. Reports now say an agreement with the BOI was signed on 13 October 2026, advancing the plan. The BOI is the Sri Lankan body that oversees investment zones, and the project operates under its oversight.

The partners say the plant will make pharmaceutical products mainly for Sri Lanka’s retail market. A report on the October agreement adds that phase one will cover oral solid dosage forms, meaning tablets and capsules, and that the investment will be phased. We could not find an official breakdown of the products.

Why Sri Lanka pharmaceutical manufacturing matters to the partners

The announcement lists several goals: technology transfer, local manufacturing capability, employment, reduced import dependence, and better affordability and availability of medicines. One Sri Lankan report puts expected employment at about 300 jobs, a figure we have not seen in the company statement. The same report says the first locally made products are expected in 2028.

Sunshine Holdings’ group chief executive, Shyam Sathasivam, described the venture in the announcement as “a strategic investment in Sri Lanka’s healthcare security and industrial growth.” Sunshine’s chairman, Vish Govindasamy, said it supports the country’s push for domestic production in essential sectors, according to a report of the launch.

How the Sri Lanka pharmaceutical manufacturing business model works

Reports of the June launch say the venture will not depend on a government buy-back guarantee. Sathasivam was quoted as saying the partners “did not need to depend on government sales.” The plant is aimed at the private retail market instead. The announcement also says products will comply with the rules of the National Medicines Regulatory Authority and applicable pricing frameworks, with the Ministry of Health among the stakeholders.

Zydus brings manufacturing expertise and technical know-how. Zydus Lifesciences’ managing director, Dr Sharvil Patel, said “strong local capabilities are key to resilient healthcare ecosystems.” Sunshine contributes local market presence and distribution; Patel noted the group has marketed products in Sri Lanka for over 30 years. Zydus describes itself as a global life-sciences company with 30,000 employees, including 1,500 R&D scientists, while Sunshine runs distribution, retail pharmacy, manufacturing and medical devices in Sri Lanka. More background is on Sunshine Holdings.

The group’s chairman also said it wants to explore a once-daily, three-in-one blood-pressure pill developed by the University of Kelaniya. That is an intention, not a plan with a date.

What it could mean for patients and pharmacies in Sri Lanka

For patients, the practical question is whether locally made tablets and capsules arrive at prices and volumes that change what pharmacies can stock. The announcement points to better availability and affordability as goals, but it gives no price targets, volumes or product names, so those are aims rather than outcomes. For pharmacies and distributors, a local manufacturer that sits inside a group with its own distribution and retail businesses could shorten supply chains. Whether that benefit reaches independent pharmacies is not addressed in anything we reviewed. A plant of this size would also take time to ramp up after 2028, so any effect on supply is likely to be gradual.

Risks and caveats for Sri Lanka pharmaceutical manufacturing

• The 2028 start date is conditional on construction progress and regulatory approvals.
• Capacity, product list and revenue targets have not been disclosed, so the plant’s real impact on supply cannot yet be sized.
• The $20 million figure is a commitment for the whole project. It should not be read as Zydus’s own cheque; a report on the company’s stock-exchange disclosure says Zydus will subscribe to a 50% stake for up to $5 million.
• Pricing rules and a retail-only model leave the venture exposed to market and regulatory changes.

In our assessment, the Sri Lanka pharmaceutical manufacturing plant is best read as a modest, carefully scoped step. The local-supply case is plausible, but the evidence on volumes and prices is not yet public, so the benefit to patients remains unproven. For readers following broader drug-development news, see our earlier report on a Zydus trial and pharmaceutical coverage.

What to watch next in Sri Lanka pharmaceutical manufacturing

• Start of construction and any regulatory approvals from the NMRA.
• A product list and capacity figures.
• Hiring and technology-transfer announcements.
• Whether the venture adds export markets later. Nothing in the announcements says so.

Questions about Sri Lanka pharmaceutical manufacturing and the Zydus plant

Who is building the Sri Lanka pharmaceutical manufacturing plant?

Zydus Sunshine Lifesciences, a joint venture between Zydus Lifesciences of India and Sunshine Healthcare of Sri Lanka.

Where will it be located?

In the BOI zone in Horana, Sri Lanka, on nearly four acres.

How much will it cost, and when will it open?

The investment is planned at more than $20 million, with commercial operations expected from 2028.

What will it make?

Pharmaceutical products mainly for Sri Lanka’s retail market. A report says phase one covers tablets and capsules.

How we reported this: we relied on the Zydus Lifesciences and Sunshine Healthcare announcement of 26 June 2026 and on reports of the October agreement, because we could not read the company filing itself. Details we could not confirm from official text are attributed to reports. Last updated: 15 October 2026. This article is news reporting and not investment advice.